Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Haemonetics Co. stock logo
HAE
Haemonetics
$87.65
+1.7%
$79.71
$70.74
$95.26
$4.45B0.36448,742 shs431,155 shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$111.27
-4.4%
$111.45
$70.24
$137.11
$3.46B1.3424,247 shs412,846 shs
Nevro Corp. stock logo
NVRO
Nevro
$11.61
-7.2%
$14.16
$11.49
$34.86
$425.86M0.89474,770 shs346,380 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$35.56
+1.3%
$30.51
$13.82
$40.74
$2.30B1.121.73 million shs1.57 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Haemonetics Co. stock logo
HAE
Haemonetics
+1.36%+1.59%+5.16%+6.14%+3.72%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
+0.08%+4.43%+3.36%-1.51%-13.66%
Nevro Corp. stock logo
NVRO
Nevro
-2.19%+1.95%-8.21%-30.66%-61.71%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+0.43%+10.61%+16.68%+52.76%-3.33%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Haemonetics Co. stock logo
HAE
Haemonetics
4.0599 of 5 stars
2.32.00.04.32.91.72.5
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
2.1685 of 5 stars
0.00.01.73.80.61.72.5
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.6575 of 5 stars
2.51.00.00.02.20.80.6
Nevro Corp. stock logo
NVRO
Nevro
1.7153 of 5 stars
4.02.00.00.00.01.70.6
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
3.1742 of 5 stars
2.22.00.04.93.50.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6719.41% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
3.00
Buy$135.1121.43% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2382.87% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.45
Hold$39.4510.95% Upside

Current Analyst Ratings

Latest IRTC, HRC, TNDM, HAE, and NVRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$34.00 ➝ $45.00
4/23/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$37.00 ➝ $40.00
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
4/3/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$31.00 ➝ $38.00
3/26/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$24.00 ➝ $37.00
3/15/2024
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$25.00 ➝ $31.00
2/23/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$142.00 ➝ $133.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.81$5.13 per share17.10$16.22 per share5.40
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$492.68M7.03N/AN/A$6.85 per share16.24
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.00N/AN/A$8.10 per share1.43
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$747.72M3.07N/AN/A$4.81 per share7.39

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4635.6320.672.019.97%22.37%9.71%5/9/2024 (Confirmed)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$123.41M-$4.05N/AN/AN/A-25.05%-56.38%-28.63%5/2/2024 (Confirmed)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$3.44N/AN/AN/A-29.77%-31.48%-10.75%5/2/2024 (Confirmed)

Latest IRTC, HRC, TNDM, HAE, and NVRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
5/2/2024N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.99N/A+$0.99N/AN/AN/A  
5/2/2024N/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.80N/A+$0.80N/AN/AN/A  
2/22/2024Q4 2023
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.60-$1.26-$0.66-$1.26$131.14 million$132.51 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/21/2024Q4 2023
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.23-$0.27-$0.04-$0.08$204.86 million$196.80 million
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.17
2.15
2.02
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
0.91
3.83
3.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.68%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
2,00031.12 million30.91 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,40064.56 million62.95 millionOptionable

IRTC, HRC, TNDM, HAE, and NVRO Headlines

SourceHeadline
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to DeclineEarnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
zacks.com - April 25 at 11:05 AM
Jennison Associates LLC Has $38.18 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Jennison Associates LLC Has $38.18 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 25 at 7:19 AM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to "Outperform" by SVB LeerinkTandem Diabetes Care (NASDAQ:TNDM) Upgraded to "Outperform" by SVB Leerink
marketbeat.com - April 25 at 7:11 AM
Tandem Diabetes Care (TNDM) to Release Earnings on ThursdayTandem Diabetes Care (TNDM) to Release Earnings on Thursday
americanbankingnews.com - April 25 at 2:14 AM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel NicolausTandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $40.00 at Stifel Nicolaus
americanbankingnews.com - April 24 at 4:02 AM
Tandem Diabetes Care IncTandem Diabetes Care Inc
morningstar.com - April 23 at 10:56 PM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel NicolausTandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus
marketbeat.com - April 23 at 1:49 PM
Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.9%Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.9%
marketbeat.com - April 23 at 1:25 PM
Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & IceCure Medical (NASDAQ:ICCM)Contrasting Tandem Diabetes Care (NASDAQ:TNDM) & IceCure Medical (NASDAQ:ICCM)
americanbankingnews.com - April 20 at 2:04 AM
Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at StockNews.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded at StockNews.com
americanbankingnews.com - April 19 at 2:14 AM
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Mirae Asset Global Investments Co. Ltd.Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Mirae Asset Global Investments Co. Ltd.
marketbeat.com - April 17 at 4:44 AM
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 2.9%Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 2.9%
marketbeat.com - April 15 at 1:55 PM
Raymond James & Associates Purchases 51,721 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Raymond James & Associates Purchases 51,721 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 15 at 4:26 AM
Validea Detailed Fundamental Analysis - TNDMValidea Detailed Fundamental Analysis - TNDM
nasdaq.com - April 14 at 11:34 AM
Tandem Diabetes Care (NASDAQ:TNDM) Downgraded by StockNews.com to SellTandem Diabetes Care (NASDAQ:TNDM) Downgraded by StockNews.com to Sell
marketbeat.com - April 11 at 11:12 PM
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
businesswire.com - April 9 at 4:05 PM
Whats Driving Tandem Diabetes Care Incs Surprising 25% Stock Rally?What's Driving Tandem Diabetes Care Inc's Surprising 25% Stock Rally?
gurufocus.com - April 9 at 12:02 PM
Bullish Tandem Diabetes Care Insiders Loaded Up On US$725.5k Of StockBullish Tandem Diabetes Care Insiders Loaded Up On US$725.5k Of Stock
finance.yahoo.com - April 9 at 8:55 AM
1 Beaten-Down Stock That Could Make You Richer1 Beaten-Down Stock That Could Make You Richer
fool.com - April 7 at 12:07 PM
Should You Invest in Tandem Diabetes Care (TNDM)?Should You Invest in Tandem Diabetes Care (TNDM)?
finance.yahoo.com - April 5 at 9:49 AM
Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $38.00Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $38.00
marketbeat.com - April 3 at 3:22 PM
Tandem Mobi automated insulin pump wins FDA nod for expanded pediatric useTandem Mobi automated insulin pump wins FDA nod for expanded pediatric use
drugdeliverybusiness.com - April 2 at 2:43 PM
Chicago Capital LLC Has $14.11 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)Chicago Capital LLC Has $14.11 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)
marketbeat.com - April 2 at 6:37 AM
Tandem Diabetes Care (NASDAQ:TNDM)  Shares Down 6.1% Tandem Diabetes Care (NASDAQ:TNDM) Shares Down 6.1%
marketbeat.com - April 1 at 3:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Hill-Rom logo

Hill-Rom

NYSE:HRC
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
iRhythm Technologies logo

iRhythm Technologies

NASDAQ:IRTC
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Tandem Diabetes Care logo

Tandem Diabetes Care

NASDAQ:TNDM
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.